Alliance Global Partners analyst Scott Henry lowered the firm’s price target on Assertio Holdings (ASRT) to $2.15 from $2.75 and keeps a Buy rating on the shares. Assertio reported Q3 results that were about in-line with the firm’s expectations, though the firm lowered its Rolvedon forecasts based on trends and “subjectively discounted our price target by 20% to account for whistleblower accusations,” the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT:
- Assertio Therapeutics Reports Strong Q3 and Board Changes
- Assertio Therapeutics’ Q3 2024 Earnings Overview
- Assertio Holdings reports Q3 EPS 3c, consensus (5c)
- Assertio Therapeutics options imply 29.1% move in share price post-earnings
- Assertio calls short-seller claims about accounting practices ‘false, baseless’
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue